Agilent Technologies

Phase A — Understand the business

Lens 1 · Company Overview

Agilent is a global leader in the analytical laboratory — instruments, software, services and consumables spanning the full lab workflow for life-sciences, diagnostics and applied markets. Spun out of Hewlett-Packard in 1999 (incorporated in Delaware, May 1999), HQ Santa Clara, CA, fiscal year ending Oct 31.

How it makes money. FY2025 net revenue $6,948M, split Products $4,944M (71%) / Services & other $2,004M (29%). The economic engine is a razor-and-blade installed base: Agilent sells chromatographs (LC, GC), mass specs (LC/MS, GC/MS, ICP-MS), spectroscopy and cell-analysis instruments (the "razor"), then monetises that base for 7-10+ years through consumables (columns, reagents, vials), service contracts, and software (the "blades"). Roughly half of revenue is recurring/aftermarket — the single most important structural fact about the business.

Reorganised structure. As of FY2025 Agilent reports three segments under its "OneAgilent" / Ignite reorganisation (a shift from the prior LSAG / CrossLab / Diagnostics-&-Genomics structure):

• Life Sciences & Diagnostics Markets (LSDG) — $2,726M, 39% of revenue. LC, LC/MS, cell analysis, genomics (NGS, NASD oligo CDMO), pathology/companion diagnostics, and the BIOVECTRA biopharma CDMO (now "Agilent Advanced Therapeutics").
• Agilent CrossLab (ACG) — $2,908M, 42% of revenue. The services + consumables annuity across the installed base — repair, maintenance, compliance, lab automation. The highest-margin, most-recurring segment.
• Applied Markets — $1,314M, 19% of revenue. GC, ICP-MS, spectroscopy and vacuum for chemical/advanced-materials, food, energy, environmental and forensics end markets.

End markets, in rough order of size: pharma/biopharma (largest), chemical & advanced materials, diagnostics & clinical, food, academia & government, environmental & forensics.

Customers / suppliers / competitors. No single customer is ≥10% of revenue in 2025, 2024 or 2023 — very low customer concentration. Customers are pharma QC/R&D labs, CROs/CDMOs, hospital and clinical-diagnostic labs, chemical and food companies, and academic/government labs. Primary competitors: Waters, Thermo Fisher, Danaher (SCIEX/Beckman/Cytiva), Bruker, Shimadzu, PerkinElmer/Revvity, Mettler-Toledo. Contract structure is favourable: instruments sold point-in-time; service contracts recognised straight-line over the service period; multi-year compliance/service agreements give visibility. Not take-or-pay, but the regulated-lab switching cost makes the annuity sticky.

Lens 2 · Supply Chain

Upstream inputs → Agilent → end customer, with named stakeholders:

Upstream (suppliers/inputs): electronic components and semiconductors (detectors, pumps, ion optics); precision-machined metals and specialty alloys; optics and lasers; high-purity solvents, antibodies and reagents (for the consumables/diagnostics lines); and for BIOVECTRA/NASD, biologics raw materials and synthesis reagents. Agilent manufactures across the US, Singapore (a tax-holiday hub through 2030, worth $102M of tax benefit in FY2025), Germany, China, Malaysia and the UK (BIOVECTRA, Canada). Tariffs and shipping are a live cost-chain chokepoint — they compressed gross margin across all three segments in FY2025; the IEEPA-tariff reversal in 2026 is now a tailwind (see Lens 5/10).

Agilent (transformation): instruments assembled at regional plants; consumables/columns at dedicated sites; oligos at the NASD facility (Frederick, CO + Boulder); biologics at BIOVECTRA/Advanced Therapeutics. Singapore is the chokepoint of the manufacturing footprint and the tax structure.

Downstream (channel → customer): direct salesforce (the dominant route, especially CrossLab service) + distributors for some applied/consumables lines. End buyers: pharma (Pfizer, Merck, Novartis-type QC labs — none individually >10%), CROs/CDMOs, hospital/clinical labs (pathology, companion Dx), chemical/food/energy companies, and academic/government institutions.

Chokepoints / single-source dependencies: (1) Singapore manufacturing + tax holiday — concentration risk if the 2030 renewal lapses; (2) specialty reagents/antibodies for diagnostics (the Biocare deal partly in-sources this); (3) tariff/logistics on cross-border instrument shipments — the most material near-term swing factor. Names-or-it-didn't-happen note: the filing does not disclose named single-source suppliers; the chokepoints above are structural, sourced from the 10-K's manufacturing and tax disclosures rather than a named-supplier list.

Lens 3 · Competitive Advantages (moats)

The moat is real and of the durable kind — installed base + regulatory switching costs. Five reinforcing layers:

1. Installed-base lock-in. Every instrument placed seeds a decade of consumables + service revenue. CrossLab (42% of revenue, 32.5% operating margin) is the moat monetised.
2. Regulatory switching costs. In GxP/regulated pharma and clinical-diagnostic labs, an instrument and method are validated into SOPs and regulatory filings. Switching vendors means re-validation — expensive, slow, risk-laden. This is the single most under-appreciated source of pricing power.
3. Brand / reliability. Agilent (and ex-HP heritage) is a trusted name in QC labs where a failed analysis has regulatory consequences. Reliability beats spec-sheet competition.
4. Scale + breadth. Full-workflow coverage (instrument + column + reagent + software + service) lets Agilent sell the lab, not the box. Hard for a point-product rival to replicate.
5. Process / IP. Decades of chromatography and MS engineering; the NASD oligo and BIOVECTRA biologics capabilities add a manufacturing moat in a supply-constrained niche.

Bargaining power. Over customers: moderate-to-high in the recurring base (re-validation cost), lower on new instrument placements (competitive, capex-sensitive). Over suppliers: moderate — components are sourced competitively, but tariffs/logistics showed Agilent is a price-taker on the input cost chain. Pricing actions (targeted increases) partly offset this in FY2025-26. Ground: positioning.md / bottlenecks.md are missing from the commercial layer for the genomics topic, so this lens is filing + web-grounded.

Lens 4 · Segments

Revenue and operating income by segment (FY, $M):

(Total reportable segment income $1,783M reconciles to GAAP income from operations $1,479M after $304M unallocated: amortization $104M, transformational initiatives $69M, restructuring $82M, acquisition/integration $19M, other $30M.)

Geography (FY2025, $M): US $2,342 (34%), China incl. HK $1,224 (18%), Rest of world $3,382 (49%). Total $6,948.

Trend & cause. The decisive read: the cycle has turned. LSDG swung from −11% (FY2024) to +11% (FY2025), driven by pharma capex normalising, the CDMO (BIOVECTRA, ~5pts of LSDG growth) and companion-diagnostics/pathology strength. CrossLab is the steady compounder (+3% → +6%), proving the annuity thesis — it grew even through the FY2024 instrument downturn. Applied is the laggard, just inflecting positive (+1%) after −7% in FY2024. Q2 FY2026 confirms acceleration across the board: LSDG +12%, CrossLab +6%, Applied +14%. Margin caveat: LSDG operating margin (19.7%) is structurally below CrossLab (32.5%) and is being further diluted by the lower-margin BIOVECTRA/Advanced-Therapeutics CDMO mix — a deliberate trade of margin for growth + recurring non-instrument revenue.

---

Phase B — Measure performance

Lens 5 · Earnings Result (Q2 FY2026, reported 27 May 2026)

The decisive print of the cycle — a clean beat-and-raise that drove a ~+17% one-day stock move.

• Revenue $1,835M, +10.0% reported / +6.3% core vs Q2 FY2025 $1,668M. FX was a ~+4pt tailwind (weak dollar), so core ~6% — a genuine reacceleration, not just currency.
• GAAP net income $339M (EPS diluted $1.20) vs $215M ($0.75) — up 60%. Non-GAAP EPS $1.49, +14% YoY.
• Margins inflecting. Non-GAAP operating margin 26.4%, +130bps YoY and +180bps sequential. GAAP operating margin 21.7% ($399M/$1,835M) vs 18.0% prior year. Margin recovery driven by volume leverage, pricing, decreased tariffs, restructuring savings and Ignite, partly offset by wages/variable pay.
• Guidance RAISED. FY2026 non-GAAP EPS to $6.00–$6.10 (from prior), revenue $7.39–$7.49B, core growth 4.5–6.0%, ~85bps non-GAAP operating-margin expansion at the midpoint.
• Balance-sheet flags — clean. Cash $1,807M (Apr-30) vs $1,789M (Oct-31); senior notes carrying $3,333M (fair value $3,182M). H1 FY2026 OCF healthy; capex $169M (down from $211M H1 prior). Receivables and inventory in line with the revenue ramp — no working-capital red flag.
• Market reaction (~+17%) says expectations had been set for a slower recovery; the core reacceleration + margin beat + raise repriced the recovery timeline. What was priced in: a muted, drawn-out lab-tools recovery. What surprised: the speed of margin inflection and the capex-normalisation commentary.
• Unusual vs own history: the +180bps sequential non-GAAP margin jump is large for this company; the IEEPA tariff reversal is a one-off swing in the cost line (see Lens 10).

Lens 6 · Earnings Calls (sentiment trend)

Transcripts not on the research-layer shelf (transcripts=0); this lens is web-grounded.

Tone has inflected from defensive to confident over the last ~4 quarters. Through FY2024 and early FY2025, management language centered on "constrained capital spending," cost discipline and cautious end-market commentary. By Q1-Q2 FY2026 the framing flips to "customers' ability to spend capital budgets has begun to normalize", broad-based demand, instrument-replacement momentum and Ignite-driven productivity.

Recurring phrases (now): "Ignite Operating System," "instrument replacement cycle," "broad-based demand," "core growth," "margin expansion," "differentiated solutions" (e.g. the new 9500 ICP-MS). What they stopped saying: the persistent "constrained/cautious capex" refrain that dominated FY2024. The one caution they kept: customers funded by the US federal government (academic/government) remain soft — management explicitly carves them out of the normalization narrative. CFO Adam Elinoff (TD Cowen, Mar 2026): the FY2026 NIH funding uptick "has yet to filter through as the labs are continuing to be conservative".

Lens 7 · Comps

Life-science-tools peer set.

Read: Agilent sits mid-pack on EV/EBITDA — richer than Waters (~15x), cheaper than Mettler (~21x), roughly in line with Thermo (~18x). It is not the cheap name in the group, nor the most expensive. The market is paying a quality multiple for a recovering-but-not-hypergrowth annuity business. A discount to MTD is defensible (lower margin, slower historical growth); a premium to WAT is harder to justify now that Waters has scale-doubled via BD. Wells Fargo cut its PT "on valuation" — the explicit bear data point.

Lens 8 · Stock-Price Catalysts (last ~5 years)

What actually moves A:

• 2021 peak ($173.36, Sep-2021): post-COVID lab-spending boom + pharma/biopharma capex surge.
• 2022-2023 de-rate: rates up, multiple compression, then the biopharma/pharma capex downturn — China softness + customers cutting instrument budgets. FY2023 Q4 revenue −8.7%; the LSAG instrument business fell ~17%.
• 2023-2024 trough (~$110-130): core revenue declines (FY2024 ~−5% core), the worst lab-tools cycle in a decade. Stock bottomed on the capex-cut narrative.
• 2024 — Resolution Bioscience exit (FY2023 impairment ~$277M) and the CEO transition (Padraig McDonnell, 1 May 2024).
• 2024 — BIOVECTRA acquisition (~$862M) — the biopharma-CDMO bet.
• Q2 FY2026 (+~17%, May-2026): the beat-and-raise that confirmed the recovery + margin inflection — the single biggest up-move of the period.
• 2026 — Biocare ($950M) + Waters/BD merger close — strategic-landscape catalysts.

Pattern: A is a capex-cycle + margin-narrative stock. It reacts hardest to (1) the pharma/biopharma instrument-spending cycle, (2) guidance revisions (beat-and-raise vs cut), and (3) China demand. Single-customer risk is negligible (no >10% customer); macro/end-market cyclicality is the dominant driver. It is not a binary-event stock.

---

Phase C — Judge people & books

Lens 9 · Management

• CEO Padraig McDonnell — appointed 1 May 2024. Track record: internal promotion; previously ran Agilent's services (CrossLab) business and customer-experience transformation — i.e. he built the highest-margin, most-recurring segment. That is the right pedigree for a company whose thesis is "monetise the installed base.".
• Ignite Operating System — his signature program: a 3-year transformation that found ~$80M in savings, collapsed 21 product lines into 6 groupings, and removed management layers. This is a genuine, quantified operational story — and it is showing up in the margin line (Q2 +130bps YoY).
• CFO Adam Elinoff — recently appointed. CTO August Specht — recently appointed, folded into Ignite's innovation push. A refreshed top team executing a coherent self-help plan.
• Tenure & skin in the game: insider ownership ~0.28% — low, typical of a mature non-founder spinout; no founder-owner. Don't expect founder-style alignment; this is a professional-manager company.
• Capital allocation: disciplined and shareholder-friendly. FY2025 returned ~$707M (buybacks $425M + dividends $282M) on ~$1.15B FCF. Multi-year buyback authorisations, a growing dividend, bolt-on M&A (BIOVECTRA, Biocare). ROIC ~11.8% (Jan-2026) — solid for the sector, above WACC, but not exceptional; the BIOVECTRA/Biocare deals are a bet they can push it higher via mix shift to recurring/diagnostics.
• Red flags: none material. The Resolution Bioscience exit (FY2023, ~$277M impairment) was a value-destroying liquid-biopsy bet written off — a real but contained capital-allocation miss under the prior regime. No related-party issues, no promotional behavior, comp appears standard. Archetype: professional operator, not visionary founder — fits a steady-compounder, self-help stage.

Lens 10 · Forensic Red Flags

Forensic-analyst read across IS / BS / CF. Quality of earnings is high; this is a clean book.

• Revenue recognition: standard — point-in-time for instruments/consumables/licenses; straight-line for service contracts; multiple-performance-obligation allocation by standalone selling price. The critical-audit-matter in the 10-K is revenue recognition (routine for a multi-element-arrangement company), not a red flag.
• Cash vs earnings: OCF $1,559M vs net income $1,303M (FY2025) — OCF > NI, healthy. No earnings-quality divergence.
• Receivables/inventory vs revenue: AR up $163M to $1,487M, inventory up $53M to $1,025M on +7% revenue — receivables grew faster than revenue (a modest watch item, consistent with H2 revenue weighting and the ramp), but nothing alarming. Excess/obsolete inventory charges steady (~$45M/yr).
• SBC: $128M (1.8% of revenue) — low and stable; non-GAAP is not being flattered by aggressive SBC add-backs. A genuine positive vs many peers.
• Goodwill/intangibles: Goodwill $4,473M = 35% of total assets — elevated, the legacy of serial M&A. No impairment in FY2025 (prior Resolution Bioscience write-off already taken). Biocare ($950M) will add more goodwill — the standard acquisition-roll-up risk, but coverage is comfortable (net debt only ~$1.6B, FCF ~$1.2B).
• Leases / related parties / contingencies: ordinary. Keysight site-service/lease income (~$12M) is the only related-party item — immaterial and disclosed.
• Tax: Singapore tax holiday (extended to 2030) cut taxes $102M in FY2025 (~$0.36 diluted EPS benefit) — a real, disclosed, policy-dependent earnings prop. If the holiday lapses in 2030, ~$100M of pre-tax-equivalent benefit is at risk. Watch, don't panic.

Regulatory findings (required sub-section).

• SEC Litigation Releases / AAERs: None. "No LR found" and "No AAER found" for Agilent Technologies, 2021-06-24 → 2026-06-24, via SEC EDGAR EFTS.
• Item 3 (Legal Proceedings), most recent 10-K: ordinary-course litigation only; the 10-K discloses commitments/contingencies (Note 18) with no material adverse matter flagged.
• Non-SEC (FTC/DOJ/FDA/etc.): web search surfaced no material enforcement action, consent decree, fine or penalty against Agilent in the period. As a diagnostics maker Agilent is FDA-regulated (companion-Dx PMAs/510(k)s) — routine, not enforcement. The IEEPA tariff matter is a favourable development (refund claims filed), not an action against the company.
• Verdict: No material regulatory or legal findings — verified via SEC EDGAR EFTS (LR, AAER), web search, and 10-K Item 3 as of 2026-06-24.

---

Phase D — Project & stress-test

Lens 11 · Forward Projection (EPS, next three fiscal years)

Built bottom-up from FY2025 actuals + FY2026 guidance + consensus. Non-GAAP EPS basis (the basis on which the stock trades and management guides). FY2025 non-GAAP EPS ~$5.50-5.60; FY2026 guided $6.00-$6.10.

Inputs labeled: FY2026 = ; FY2027 base = ; FY2028 and bull/bear = `` with the arithmetic above. Long-term sector frame: revenue ~5.7%/yr, EPS ~10%/yr.

Brier forecast not logged — --watchlist breadth mode (per skill: skip forecast.ts create in the loop; log only on genuine committed conviction in a /thesis pass).

Lens 12 · Bull vs Bear

Bull case. A best-in-class, ~50%-recurring lab-tools annuity whose worst cycle in a decade is over — Q2 FY2026 confirmed core reacceleration (+6.3%) and margin inflection (+130bps) simultaneously. Three compounding levers: (1) installed-base monetisation (CrossLab, 32.5% margin, grew through the downturn); (2) self-help margin expansion — Ignite is delivering quantified savings into the P&L with room to run; (3) mix shift to recurring/diagnostics via Biocare (pathology/companion-Dx) and BIOVECTRA (biopharma CDMO), lifting non-instrument revenue and structural growth. Tariff reversal is a 2026 tailwind. Capital allocation is clean (FCF ~$1.2B, buybacks + dividend + accretive bolt-ons). Earnings surprise potential: the instrument-replacement cycle (instruments bought in the 2020-21 boom hit end-of-life ~2026-28) could drive a multi-year placement upcycle the Street is under-modelling.

Bear case (permanent-impairment lens). (1) It's a quality cyclical, already priced for recovery — at ~20x forward EPS with ~5% core growth, the multiple already embeds the rebound; a stall (China, academic/government, capex pause) compresses both EPS and multiple. (2) Competitive intensity just stepped up — Waters + BD Biosciences (closed Feb-2026, ~$6.5B revenue, ~$40B TAM) creates a scaled LC/MS + flow-cytometry + diagnostics rival precisely in Agilent's core; Thermo and Danaher dwarf it on R&D. (3) Margin mix drag — BIOVECTRA/Advanced-Therapeutics CDMO is structurally lower-margin; growth-via-lower-margin-mix caps the operating-margin ceiling. Pre-mortem (18 months out, thesis broke): the capex "normalization" proved to be a one-quarter FX-flattered head-fake; academic/government weakness spread to pharma; China kept sliding; the stock de-rated from ~20x to ~16x on decelerating core growth, taking it back toward $105-110. Multiples too high? Not egregiously — mid-pack — but there is no valuation cushion; this is priced as a winner. Contrarian view the market refuses to see: the bears under-weight how defensive the 50% recurring base is — even a disappointing instrument cycle leaves CrossLab compounding, which is why the downside is a de-rate, not a collapse.

Lens 13 · Devil's Advocate (short-seller)

Dismantling the bull case. What structurally breaks Agilent?

• Revenue concentration: not by customer (none >10%) but by end market and geography — pharma/biopharma capex is the swing factor; China (18% of revenue) is structurally decelerating and politically exposed (bio-supply-chain decoupling, BIOSECURE-type risk, local-champion substitution). A China air-pocket hits hard.
• The moat is weaker than bulls think where? On new instrument placements — that's a genuinely competitive, capex-sensitive market where Shimadzu (price), Waters (now scaled), Thermo and Danaher all push. The annuity is sticky; winning the next box is not. If Agilent loses placement share in the upcycle, the future annuity erodes.
• Most dangerous competitor bulls underestimate: Waters post-BD. The Reverse Morris Trust closed Feb-2026; Waters doubled its TAM to ~$40B and bolted flow cytometry + diagnostics onto best-in-class LC/MS — a direct, now-larger assault on Agilent's core chromatography/MS franchise. Bulls treat Waters as the small peer; that's stale.
• Worst capital-allocation moves: Resolution Bioscience (liquid biopsy, ~$277M impairment, exited) — a failed adjacency bet. Goodwill is 35% of assets from serial M&A; Biocare adds more. The roll-up could mask organic-growth softness with acquired revenue.
• Assumptions that must hold for today's price: (1) capex normalization is durable, not FX-flattered; (2) ~85bps/yr margin expansion sustains despite CDMO mix drag; (3) China stabilises; (4) academic/government weakness stays contained. If core growth disappoints by 20-30% (say ~3.5% instead of ~5-6%), the beat-and-raise narrative reverses, the multiple compresses to ~16x, and the stock revisits ~$105-110 — ~15-20% downside from ~$130.
• Single scenario that permanently impairs: a structural China share-loss to local champions + a secular shift of pharma QC to lower-cost Asian instrument vendors — plausibility low-to-moderate, slow-moving, and partly hedged by the regulated-lab switching cost. The cyclical bear (capex stall) is far more probable than the structural one.

Lens 14 · Management Questions (ordered by information value)

1. Q2 core growth was +6.3% with a +4pt FX tailwind — strip out FX and currency-driven pull-forward: what is the true underlying instrument-demand run-rate, and how much is durable replacement-cycle vs a one-quarter restock?
2. With Waters + BD now a ~$6.5B scaled LC/MS + diagnostics competitor, where specifically are you gaining vs losing new-instrument placement share, by modality and region?
3. Academic/government customers remain soft on US-federal funding — quantify that revenue exposure, and what is the realistic timing for NIH-funded demand to convert?
4. China is 18% of revenue and decelerating — what is your structural (not cyclical) China thesis given local-champion substitution and bio-supply-chain decoupling?
5. Ignite delivered ~$80M of savings — what is the remaining identified savings runway, and what is the steady-state operating-margin ceiling for this portfolio?
6. BIOVECTRA/Advanced Therapeutics is margin-dilutive but high-growth — at what revenue scale does it stop dragging consolidated margin, and what return are you underwriting?
7. Biocare ($950M) is EPS-accretive ~year-2 — what is the revenue-synergy case in pathology/companion-Dx, and how does it change the recurring-revenue mix?
8. The Singapore tax holiday (worth ~$0.36 EPS) renews in 2030 — what is the plan if it lapses or is renegotiated less favourably?
9. The 2020-21 instrument boom implies a replacement wave ~2026-28 — how large could that upcycle be, and is your guidance modelling it conservatively?
10. ROIC is ~11.8% — what is the multi-year target, and which mix shifts (diagnostics, services, consumables) drive it?
11. IEEPA tariffs were invalidated and refund claims filed — quantify the FY2026 cost tailwind and the potential one-time refund, and how you'll treat it.
12. Capital allocation priority over the next three years: buybacks vs dividend growth vs M&A — and what M&A size/type is on the table after Biocare?
13. What is your AI/software/informatics strategy across the lab workflow, and can it become a third recurring leg beyond consumables and service?
14. Where is pricing power strongest vs weakest across the three segments, and how much of recent growth is price vs volume?
15. What is the single end-market or technology shift that worries you most over five years, and how are you positioned for it?

---